Biogen Amevive EU Approval Will Require Comparative Studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
European approval of Biogen’s Amevive will require comparative data against other established psoriasis therapies or a larger dataset in patients refractory to or intolerant of other therapies, the firm said following a Feb. 18 hearing with the Committee for Proprietary Medicinal Products.